Mycoplasma Testing Market Size, Share & Trends Analysis By Product (Instruments, Kit & Reagents), By Technology (PCR, ELISA), By Application (Cell Line Testing, Virus Testing), By End Use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Mycoplasma Testing market size was valued at USD 811.4 million in 2021 and is predicted to hit USD 2.40 billion by 2030 with a registered CAGR of 14.2% during the forecast period 2022 to 2030.

Key Takeaways:

• By product, kits and reagents dominated the market, and are anticipated to exhibit the fastest CAGR throughout the forecast period, due to their widespread use in mycoplasma testing
• By technology, the polymerase chain reaction segment held a larger share in 2021 which can be attributed to the technology's ability to give quick and precise findings
• Ease of conducting the procedure and rapid detection are some of the major advantages offered by the PCR method
• By application, the cell line testing segment held a larger share in 2021. the increasing risk of cell line contamination
• Mycoplasma contamination can cause alterations in cell culture metabolites and lead to development of toxins. This increases the importance of cell line testing and authentication in the pharmaceutical and biopharmaceutical industries
• North America held the larger share in 2021. This is mostly attributed to the presence of significant market participants, as well as rising R&D spending and federal assistance
• In Asia Pacific, the market is expected to grow at the highest rate in a projected time period driven by factors such as the rising prevalence of target diseases with an aging population, rising awareness and others

The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Increasing investments in R&D have contributed significantly to the market’s revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period

Mycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.

Report Scope of the Mycoplasma Testing Market

Product Insights

The kits and reagents segment captured the highest revenue share of 50.7% in 2021, due to the high demand for these products in mycoplasma detection, as well as their high cost. Various market players have developed mycoplasma detection kits catering specifically to the needs of researchers and biologic manufacturers, which is fueling segment growth. Due to the growing availability of automated equipment for the detection of mycoplasma, instruments are predicted to experience substantial growth during the projected period.

A better method that enables quick detection and produces results quickly is provided by PCR systems. For instance, the CFX96 Touch Real-Time PCR Detection System from Bio-Rad Laboratories is based on PCR. It is a versatile and accurate PCR detection system with six channels that combines cutting-edge optical technique with exact temperature control. As a result, both multiplex as well as singleplex reactions can be detected using a method that is trustworthy and sensitive. Thus, propelling the mycoplasma testing market growth.

Technology Insights

The PCR segment dominated the mycoplasma testing market with a revenue share of 32.1% in 2021 and exhibits the fastest growth rate during the projected period. This approach allows the separation of other contaminating DNA while allowing the detection of various mycoplasma species. It offers test findings that are highly efficient and specific. Some of the key benefits provided by this technology includes ease of use and quick detection. For instance, the Merck KGaA-developed LookOut Mycoplasma PCR Detection Kit that makes it easier to detect contamination with Ureaplasma, Mycoplasma, and Acholeplasma in cell-derived biologicals and cell culture lines.

ELISA technology is expected to gain considerable market share during the forecast period as it facilitates easy detection with the use of labeled probes or antibodies for mycoplasma detection. In some instances, PCR and ELISA tests are combined to form PCR-ELISA, a photometric enzyme-based immunoassay that facilitates the detection of PCR-amplified mycoplasma DNA in samples. Functional advantages, cost-effectiveness, and ability to detect a wide range of strains are few factors propelling segment growth during the forecast period.

Application Insights

The cell line testing segment accounted for the largest share of 41.3% in 2021, as well as the fastest growth rate throughout the forecast period, owing to the increase in research projects being done in the field of cell culture. For instance, the federal funding agency in Canada for health research, Canadian Institutes of Health Research (CIHR), has supported many health researchers in Canada with around USD 981 million in investments. The National Research Council’s Industrial Research and Assistance Program (NRC-IRAP) is also offering technical support to several Canadian life science companies including small and medium-scale involved in product development and innovation.

A surge in mycoplasma contamination in cell culture is also anticipated to cause it to see the largest growth during the projection period. Toxin development and changes in metabolite production in cell culture can be caused by mycoplasma contamination. As a result, cell line testing and authentication are given the utmost significance in the biopharmaceutical and pharmaceutical industries.

End-use Insights

The pharmaceutical and biotechnology companies segment received highest revenue shares of 36.2% in 2021, as well as the fastest CAGR throughout the forecast period. Because these firms have made significant investments in R&D efforts, which have fostered advancements in the field of drug development research. These businesses carry out quality tests on raw materials to manage biological safety. Furthermore, the prevalence of disorders like rheumatoid arthritis and psoriasis is rising, which is contributing to the growth of the biopharmaceutical industry.

Due to the expanding research services offered by these firms, contract research organizations (CROs) are predicted to grow profitably over the projected period. In order to ensure the sterility of cultures used in preclinical research and biopharmaceutical development, they mandate the use of mycoplasma tests, ensuring the caliber of the outsourced testing services.

Regional Insights

North America dominated the market and accounted for revenue share of 40.0% in 2021. Due to its established healthcare sector and the increased incidence of respiratory disorders, this area is predicted to enhance its market share. The existence of multinational pharmaceutical and biotech companies as well as increased investment in R&D activities in the region are additional factors promoting the expansion of this region.

Asia Pacific is estimated to witness an exponential CAGR during the projected timeframe, which can be attributed to increase in healthcare spending and rise in the demand for better infrastructure in laboratory & clinical research. Furthermore, regulatory policies imposed by healthcare organizations favoring improvements in biosafety quality are likely to surge growth opportunities in the future.

In addition, emerging markets such as India are also witnessing lucrative opportunities in this sector. the Indian government is implementing a variety of strategic efforts to encourage more Research and innovation for the development of new medication, propels the market growth.

Some of the prominent players in the Mycoplasma Testing Market include:

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Lonza Group AG
• Charles River Laboratories International, Inc.
• PromoCell GmbH
• American Type Culture Collection
• Asahi Kasei Medical Co., Ltd.
• Sartorius AG
• InvivoGen
• Eurofins Scientific 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Mycoplasma Testing market

• Product
• Instruments
• Kits & Reagents

• PCR Assays
• Nucleic Acid Detection Kits
• Stains
• Elimination Kits
• Standards & Controls
• Others
• Services
• Technology
• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods
• Application
• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others
• End-use
• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Mycoplasma Testing industry analysis from 2022 to 2030 to identify the prevailing Mycoplasma Testing industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Mycoplasma Testing industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Mycoplasma Testing industry trends, key players, market segments, application areas, and market growth strategies.